PD-L1 targeted antibody induced tumor shrinkage in several cancer types

The investigational drug MPDL3280A, an engineered PD-L1 targeted antibody, significantly improved tumor shrinkage rates in patients with locally advanced or metastatic solid tumors that progressed despite prior treatments, according to study results.The PD-L1 protein acts as a disguise, hiding cancer cells from the immune system. However, when the MPDL3280A (Genentech) antibody attaches to this protein, the cancer cells are no longer hidden and the body is able to fight the cancer.

No tags for this post.

Leave a Reply